| 1. |
Russo, Andrew F: Calcitonin Gene-Related Peptide (CGRP): A New Target for Migraine. -
United States: Annual Reviews, 2015
In: Annual review of pharmacology and toxicology. (2015) S. 533-552, ISSN 0362-1642
 Zeitschriftenartikel |
|
|
| 2. |
Deen, Marie: Blocking CGRP in migraine patients – a review of pros and cons. -
Milan: Springer Milan, 2017
In: Journal of headache and pain. (2017) S. 96-96, ISSN 1129-2369
Zeitschriftenartikel |
|
|
| 3. |
Edvinsson, Lars: CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. -
England: John Wiley & Sons, Ltd, 2015. - 7 S.
In: British journal of clinical pharmacology. (2015) S. 193-199, ISSN 0306-5251
Zeitschriftenartikel |
|
|
| 4. |
Dodick, David W: ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. -
London, England: SAGE Publications, 2018
In: Cephalalgia. (2018) S. 1026-1037, ISSN 0333-1024
Zeitschriftenartikel |
|
|
| 5. |
Ho, Tony W: Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. -
London, England: SAGE Publications, 2016
In: Cephalalgia. (2016) S. 148-161, ISSN 0333-1024
Zeitschriftenartikel |
|
|
| 6. |
Dodick, David W: Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. -
United States: American Medical Association, 2018
In: JAMA : the journal of the American Medical Association. (2018) S. 1999-2008, ISSN 0098-7484
Zeitschriftenartikel |
|
|
| 7. |
Bigal, Marcelo E.: Calcitonin Gene-Related Peptide (CGRP) and Migraine Current Understanding and State of Development. -
United States: Blackwell Publishing Ltd, 2013. - 15 S.
In: Headache. (2013) S. 1230-1244, ISSN 0017-8748
Zeitschriftenartikel |
|
|
| 8. |
Bigal, Marcelo E.: Therapeutic antibodies against CGRP or its receptor. -
England: BlackWell Publishing Ltd, 2015. - 10 S.
In: British journal of clinical pharmacology. (2015) S. 886-895, ISSN 0306-5251
Zeitschriftenartikel |
|
|
| 9. |
Charles, Andrew: Targeting calcitonin gene-related peptide: a new era in migraine therapy. -
England: Elsevier Ltd, 2019
In: The Lancet (British edition). (2019) S. 1765-1774, ISSN 0140-6736
Zeitschriftenartikel |
|
|
| 10. |
Sun, Hong, MD: Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. -
England: Elsevier Ltd, 2016
In: Lancet neurology. (2016) S. 382-390, ISSN 1474-4422
Zeitschriftenartikel |
|
|
| 11. |
MaassenVanDenBrink, Antoinette: Wiping Out CGRP: Potential Cardiovascular Risks. -
England: Elsevier Ltd, 2016
In: Trends in pharmacological sciences (Regular ed.). (2016) S. 779-788, ISSN 0165-6147
Zeitschriftenartikel |
|
|
| 12. |
Dodick, David W, Prof: Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. -
England: Elsevier Ltd, 2014
In: Lancet neurology. (2014) S. 885-892, ISSN 1474-4422
Zeitschriftenartikel |
|
|
| 13. |
Sacco, Simona: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. -
Milan: Springer Milan, 2019
In: Journal of headache and pain. (2019) S. 6-6, ISSN 1129-2369
Zeitschriftenartikel |
|
|
| 14. |
Ashina, Messoud: Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. -
London, England: SAGE Publications, 2018
In: Cephalalgia. (2018) S. 1611-1621, ISSN 0333-1024
Zeitschriftenartikel |
|
|
| 15. |
Dodick, David W, Prof: Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. -
England: Elsevier Ltd, 2014
In: Lancet neurology. (2014) S. 1100-1107, ISSN 1474-4422
Zeitschriftenartikel |
|
|
| 16. |
Ho, Tony W: Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. -
United States: American Academy of Neurology, 2014
In: Neurology. (2014) S. 958-966, ISSN 0028-3878
Zeitschriftenartikel |
|
|
| 17. |
Shi, Licheng: Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor. -
United States, 2016
In: The Journal of pharmacology and experimental therapeutics. (2016) S. 223-231, ISSN 1521-0103
Zeitschriftenartikel |
|
|
| 18. |
Melo-Carrillo, Agustin: Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors. -
United States: Society for Neuroscience, 2017
In: The Journal of neuroscience. (2017) S. 10587-10596, ISSN 0270-6474
Zeitschriftenartikel |
|
|
| 19. |
Diener, Hans-Christoph, Prof: New therapeutic approaches for the prevention and treatment of migraine. -
England: Elsevier Ltd, 2015
In: Lancet neurology. (2015) S. 1010-1022, ISSN 1474-4422
Zeitschriftenartikel |
|
|
| 20. |
Mason, Bianca N: Induction of Migraine-Like Photophobic Behavior in Mice by Both Peripheral and Central CGRP Mechanisms. -
United States: Society for Neuroscience, 2017
In: The Journal of neuroscience. (2017) S. 204-216, ISSN 0270-6474
Zeitschriftenartikel |
|
|
Suchhistorie (1 Recherche)
Jahr
